O’Leary, Kathleen A.
Bates, Amber M.
Jin, Won Jong
Burkel, Brian M.
Sriramaneni, Raghava N.
Emma, Sarah E.
Nystuen, Erin J.
Sumiec, Elizabeth G.
Ponik, Suzanne M.
Morris, Zachary S.
Schuler, Linda A.
Funding for this research was provided by:
National Institutes of Health (R01 CA179556, U01 CA2331-03, R01 CA179556)
UWCCC Borden Family Interdisciplinary Cancer Immunology-Immunotherapy Pilot Project
Article History
Received: 20 February 2023
Accepted: 5 June 2023
First Online: 13 June 2023
Declarations
:
: Animals were housed and treated under protocols approved by the Institutional Animal Care and Use Committee at the University of Wisconsin-Madison.
: Not applicable.
: ZSM is a member of the scientific advisory board for Archeus Technologies and Seneca Therapeutics and received equity options for these companies. ZSM is an inventor on patents or filed patents managed by the Wisconsin Alumni Research Foundation relating to the interaction of targeted radionuclide therapies and immunotherapies, nanoparticles designed to augment the anti-tumor immune response following radiation therapy, and the development of a brachytherapy catheter capable of delivering intra-tumor injectables.